Heart transplant breakthrough: new drug may shield kidneys from failure

NCT ID NCT04180085

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 16, 2026 · Updated 14 times

Summary

This study tests whether belatacept, a drug that suppresses the immune system without harming the kidneys, can help heart transplant patients at high risk of chronic kidney disease. About 25 participants will receive belatacept along with reduced doses of standard immunosuppressants. The goal is to improve kidney function without increasing the chance of organ rejection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bertrand Lelong
RECRUITING

Rennes, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Claire Garandeau
RECRUITING

Nantes, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Karine Nubret
RECRUITING

Bordeaux, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Laurent Sebbag
RECRUITING

Lyon, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEART TRANSPLANT FAILURE